These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35062770)

  • 21. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
    Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F
    Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
    Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
    Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.
    Chansaenroj J; Suntronwong N; Kanokudom S; Assawakosri S; Yorsaeng R; Vichaiwattana P; Klinfueng S; Wongsrisang L; Srimuan D; Thatsanatorn T; Thongmee T; Auphimai C; Nilyanimit P; Wanlapakorn N; Sudhinaraset N; Poovorawan Y
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.
    Park S; Gatchalian KK; Oh H
    Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease.
    Wang C; Chen LY; Lu QB; Cui F
    Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China.
    Zeng G; Xu L; Feng S; Tang J; Wang X; Li G; Gan Y; Zheng C; Zhao J; Yang Z
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia.
    Batmunkh B; Otgonbayar D; Shaarii S; Khaidav N; Shagdarsuren OE; Boldbaatar G; Danzan NE; Dashtseren M; Unurjargal T; Dashtseren I; Dagvasumberel M; Jagdagsuren D; Bayandorj O; Biziya B; Surenjid S; Togoo K; Bat-Erdene A; Narmandakh Z; Choijilsuren G; Batmunkh U; Soodoi C; Boldbaatar EA; Byambatsogt G; Byambaa O; Deleg Z; Enebish G; Chuluunbaatar B; Zulmunkh G; Tsolmon B; Gunchin B; Chimeddorj B; Dambadarjaa D; Sandag T
    PLoS One; 2023; 18(12):e0295167. PubMed ID: 38064430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy.
    Matula Z; Gönczi M; Bekő G; Kádár B; Ajzner É; Uher F; Vályi-Nagy I
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine.
    Toback S; Marchese AM; Warren B; Ayman S; Zarkovic S; ElTantawy I; Mallory RM; Rousculp M; Almarzooqi F; Piechowski-Jozwiak B; Bonilla MF; Bakkour AE; Hussein SE; Al Kaabi N
    Vaccine; 2024 Mar; 42(7):1777-1784. PubMed ID: 38365482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of Vaccination in Preventing COVID-19: A Community Study Comparing Four Vaccines.
    Kokić Z; Kon P; Djurković-Djaković O
    Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2.
    Szabó E; Modok S; Rónaszéki B; Faragó A; Gémes N; Nagy LI; Hackler L; Farkas K; Neuperger P; Balog JÁ; Balog A; Puskás LG; Szebeni GJ
    Front Med (Lausanne); 2023; 10():1176168. PubMed ID: 37529238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of heterologous COVID-19 vaccine regimens to deal with product shortage: A randomised clinical trial in an elderly population.
    Kundro MA; Losso MH; Macchia A; Pastor I; Alonso Serena M; Gestoso C; Moreno Macías L; Crupi F; Acosta MC; Ivalo S; Ghioldi M; Bouzas MB; Mammana L; Zapiola I; Mazzitelli I; Varese A; Geffner J; Biscayart C; Angeleri P; Lopez E; Gentile A; Ferrante D; de Quiros FGB
    Public Health Pract (Oxf); 2022 Dec; 4():100313. PubMed ID: 36090797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
    Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
    BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study.
    Al-Rifai RH; Alhosani F; Abuyadek R; Atef S; Donnelly JG; Leinberger-Jabari A; Ahmed LA; Altrabulsi B; Alatoom A; Alsuwaidi AR; AbdelWareth L
    Front Med (Lausanne); 2022; 9():1092646. PubMed ID: 36703898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterologous prime-boost with mRNA-1273 stimulates persistent neutralising antibodies in BBIBP-CorV-vaccinated individuals.
    Sharif H; Ghani H; Ahmad L; Bagol S; Wong J; Tan CW; Zhu F; Wang LF; Naing L; Cunningham AC
    Vaccine; 2023 Nov; 41(47):6910-6913. PubMed ID: 37880070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data.
    Kumwichar P; Poonsiri C; Botwright S; Sirichumroonwit N; Loharjun B; Thawillarp S; Cheewaruangroj N; Chokchaisiripakdee A; Teerawattananon Y; Chongsuvivatwong V
    JMIR Public Health Surveill; 2024 Mar; 10():e48255. PubMed ID: 38441923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of SARS-CoV-2 infection risks after primary vaccination with BNT162b2, BBIBP-CorV, or ChAdOx1-nCOV-19 and after homologous and heterologous booster vaccinations with these vaccines and evaluation of SARS-CoV-2 reinfection profiles.
    Djorwé S; Bousfiha A; Nzoyikorera N; Nyandwi J; Kawthar B; Malki A
    Biomedicine (Taipei); 2023; 13(3):31-48. PubMed ID: 37937059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students-which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)?
    Houshmand B; Keyhan SO; Fallahi HR; Ramezanzade S; Sadeghi E; Yousefi P
    Maxillofac Plast Reconstr Surg; 2022 Jan; 44(1):3. PubMed ID: 35025010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine.
    Rákóczi É; Magócs G; Kovács S; Nagy B; Szűcs G; Szekanecz Z
    Diagnostics (Basel); 2023 Feb; 13(3):. PubMed ID: 36766663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.
    Vargas-Herrera N; Fernández-Navarro M; Cabezudo NE; Soto-Becerra P; Solís-Sánchez G; Escobar-Agreda S; Silva-Valencia J; Pampa-Espinoza L; Bado-Pérez R; Solari L; Araujo-Castillo RV
    PLoS One; 2022; 17(10):e0268419. PubMed ID: 36251630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.